CAR T cell targets under investigation for MM
| Target . | Relevant references/Clincaltrials.gov identifiers . | Distribution of expression beyond MM . | Notes . |
|---|---|---|---|
| κ light chain | Pre-clinical data64 | Normal B cells | Most MMs do not express surface light chain. This CAR is also being evaluated for NHL |
| #NCT00881920 | |||
| CD138 | #NCT01886976 | Epithelia | — |
| Lewis Y antigen | Early clinical results in AML65 | NK cells, activated monocytes and dendritic cells, and some T-cell subsets | This CAR recognizes a difucosylated carbohydrate on cell-surface proteins that are part of the Lewis blood group system. This CAR is also being evaluated for AML |
| #NCT01716364 | |||
| BCMA | Preclinical data.59 Early clinical results61 | Plasmacytoid dendritic cells | — |
| #NCT02546167 and #NCT02658929 | |||
| CS1 | Preclinical data66 | Activated T cells and NK cells | This CAR has also been evaluated preclinically in NK cells66 |
| CD38 | Preclinical data67 | Subsets of B and T cells, common myeloid progenitor | — |
| NKG2D ligands | Preclinical data68 | NKG2D ligands are stress-response proteins upregulated in many human cancers and other pathologic conditions.69 The extracellular portion of the CAR is the NKG2D receptor found on NK cells and other immune cells. This CAR is also being evaluated for AML and MDS | |
| #NCT02203825 |
| Target . | Relevant references/Clincaltrials.gov identifiers . | Distribution of expression beyond MM . | Notes . |
|---|---|---|---|
| κ light chain | Pre-clinical data64 | Normal B cells | Most MMs do not express surface light chain. This CAR is also being evaluated for NHL |
| #NCT00881920 | |||
| CD138 | #NCT01886976 | Epithelia | — |
| Lewis Y antigen | Early clinical results in AML65 | NK cells, activated monocytes and dendritic cells, and some T-cell subsets | This CAR recognizes a difucosylated carbohydrate on cell-surface proteins that are part of the Lewis blood group system. This CAR is also being evaluated for AML |
| #NCT01716364 | |||
| BCMA | Preclinical data.59 Early clinical results61 | Plasmacytoid dendritic cells | — |
| #NCT02546167 and #NCT02658929 | |||
| CS1 | Preclinical data66 | Activated T cells and NK cells | This CAR has also been evaluated preclinically in NK cells66 |
| CD38 | Preclinical data67 | Subsets of B and T cells, common myeloid progenitor | — |
| NKG2D ligands | Preclinical data68 | NKG2D ligands are stress-response proteins upregulated in many human cancers and other pathologic conditions.69 The extracellular portion of the CAR is the NKG2D receptor found on NK cells and other immune cells. This CAR is also being evaluated for AML and MDS | |
| #NCT02203825 |
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.